Peptides / Sexual health and hormones

Synthetic analog · 10 amino acids · 1,431 Da

Cetrorelix

ApprovedNot banned in sport

Cetrorelix (Cetrotide) is a GnRH antagonist approved in the US and EU to prevent an early LH surge during ovarian stimulation for fertility treatment. Studies in people tested it mostly on fertility and sex hormones, and tracked side effects. PepBank shows 436 results on cetrorelix from 67 studies in people, and 50 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Cetrotide

10 amino acids, from first to lastXXXSYXLRPA

Evidence level: Large trials in people436 of 486 results come from studies in people, including randomized trials.

Results in people

436

90% of 486 results

Results in animals

8% of 486 results

Results in lab cells

2% of 486 results

From computer models

0% of 486 results

Overview

Cetrorelix at a glance

What it is	Synthetic analog, 10 amino acids
Approval	Approved in the US and EU (Cetrotide)
In sport	Not listed as banned by WADA
Studies	83 studies with results. 82 of them gave cetrorelix, with 486 results. 436 in people40 in animals10 in lab cells
Best study in people	Randomized controlled trial with 427 people (2016)
Clinical trials	95 registered: 8 active or planned, 14 with posted results
Community use	Inhibition of premature LH surges in women undergoing controlled ovarian stimulation

The science

What is cetrorelix?

Cetrorelix is a ten-residue GnRH receptor antagonist.

Amino acids in one chain

The history of cetrorelix

1992
The oldest paper on cetrorelix in PepBank is from 1992.
2007March
A registered trial of cetrorelix started (NCT00449150).

Cetrorelix structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 10 amino acidsFrom the first amino acid to the last

X1XXSY5XL+RPA10

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Cetrorelix is a synthetic analog of 10 amino acids, with no ring, 5 changed amino acids.

Formula

C₇₀H₉₂ClN₁₇O₁₄

Molecular weight

1,431 g/mol

CAS number

120287-85-6

Target

Gonadotropin-releasing hormone receptor (gene GNRHR): antagonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 25074887, ChEMBL CHEMBL1200490, UNII OON1HFZ4BA, DrugBank DB00050

Full sequence, SMILES and InChIKey

InChIKey
SBNPWPIBESPSIF-MHWMIDJBSA-N

SMILES
C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C

See charge, composition and 3D structure on the Scientific page

The evidence

What cetrorelix studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people436 of 486 results come from studies in people, including randomized trials.

Sex hormones and fertility

357 results · 334 in people · 21 animal · 2 lab

In women undergoing IUI, cetrorelix did not significantly change clinical pregnancy rates compared with r-FSH alone. Journal of human reproductive sciences, 2016

Top results

In women undergoing IUI, cetrorelix did not significantly change clinical pregnancy rates compared with r-FSH alone. (Journal of human reproductive sciences, 2016)
In IVF patients, flexible cetrorelix administration did not significantly change LH-rise incidence compared with fixed administration. (Fertility and sterility, 2011)
In COS/IUI patients, pregnancy per patient was higher with cetrorelix plus rFSH than rFSH alone: 53.8% versus 30.8%. (Human reproduction, 2007)

Bones and joints

7 results · 7 in people

In RA patients, cetrorelix did not significantly reduce disease activity compared with placebo by day 5. Scandinavian journal of rheumatology, 2014

Top results

In RA patients, cetrorelix did not significantly reduce disease activity compared with placebo by day 5. (Scandinavian journal of rheumatology, 2014)
In RA patients with high gonadotropins, cetrorelix improved disease activity more than placebo by day 5. (PloS one, 2015)
In RA patients, cetrorelix increased ACR20 responses compared with placebo by day 5. (Scandinavian journal of rheumatology, 2014)

Cancer

9 results · 6 in people · 1 animal · 2 lab

In women with fibroids, uterine volume fell 15.6% with 4 x 5 mg cetrorelix versus 5.1% with placebo. European journal of obstetrics, gynecology, and reproductive biology, 2007

Top results

In women with fibroids, uterine volume fell 15.6% with 4 x 5 mg cetrorelix versus 5.1% with placebo. (European journal of obstetrics, gynecology, and reproductive biology, 2007)
Three cetrorelix-treated patients with platinum-resistant ovarian cancer had partial remissions lasting 9, 16, and 17 weeks. (Gynecologic oncology, 2003)
In women with fibroids, uterine volume fell 15.4% with 4 x 10 mg cetrorelix versus 5.1% with placebo. (European journal of obstetrics, gynecology, and reproductive biology, 2007)

Immune system and inflammation

8 results · 6 in people · 1 animal · 1 lab

In RA patients, cetrorelix reduced TNF-α compared with placebo by day 5. Scandinavian journal of rheumatology, 2014

Top results

In RA patients, cetrorelix reduced TNF-α compared with placebo by day 5. (Scandinavian journal of rheumatology, 2014)
In rats with BPH, cetrorelix reduced the listed inflammatory cytokine and growth factor mRNA levels versus vehicle. (The Prostate, 2011)
In lab tests, cetrorelix released more histamine than degarelix. (The Journal of pharmacology and experimental therapeutics, 2002)

Cholesterol and blood fats

5 results · 5 in people

Two cetrorelix-treated patients had a 20% cholesterol increase without requiring specific treatment. Gynecologic oncology, 2003

Top results

Two cetrorelix-treated patients had a 20% cholesterol increase without requiring specific treatment. (Gynecologic oncology, 2003)
In men, neither cetrorelix regimen led to considerable or consistent changes in lipid enzyme and transfer protein activities compared with baseline and placebo. (Experimental and clinical endocrinology & diabetes, 1999)
In normal men, cetrorelix 10 mg increased HDL cholesterol from baseline by up to 0.38 +/- 0.13 mmol/l. (Clinical endocrinology, 1994)

Kidneys and bladder

7 results · 4 in people · 3 animal

In patients with BPH, a 60 mg then 30 mg cetrorelix pamoate regimen improved urinary symptom scores by 4 points more than placebo. Urology, 2010

Top results

In patients with BPH, a 60 mg then 30 mg cetrorelix pamoate regimen improved urinary symptom scores by 4 points more than placebo. (Urology, 2010)
In patients with BPH, urine flow increased in all cetrorelix dosage groups. (Urology, 2010)
In rats with BPH, cetrorelix at 0.625 mg/kg lowered prostate weights compared with vehicle. (The Prostate, 2011)

Cetrorelix has 523 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 83 cetrorelix studies by area Open the Scientific page

Key cetrorelix studies

Studies in people come first, then studies in animals and in the lab.

People
Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
Jain et al. 2016 · Journal of human reproductive sciences · 427 people · cited by 5
3 results
People
Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial
Kolibianakis et al. 2011 · Fertility and sterility · 146 people · cited by 37
2 results
People
GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial
Allegra et al. 2007 · Human reproduction (Oxford, England) · 104 people · cited by 51
5 results
People
Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles
Tandulwadkar et al. 2023 · JBRA assisted reproduction · 100 people · cited by 4
2 results
People
Short-term treatment with a gonadotropin-releasing hormone antagonist, cetrorelix, in rheumatoid arthritis (AGRA): a randomized, double-blind, placebo-controlled study
Kåss et al. 2014 · Scandinavian journal of rheumatology · 99 people · cited by 7
6 results

All 83 Cetrorelix studies

Cetrorelix clinical trials

ClinicalTrials.gov lists 95 trials of cetrorelix. 8 are active or planned, and 14 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Phase 3terminated667 planned

Cetrotide Treatment Optimization

Phase 4terminated617 planned

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

Phase 3completed528 people

All 26 Cetrorelix trials

Status and safety

Is cetrorelix approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Cetrotide). The FDA label for Cetrotide says: “Prevention of premature LH surges during controlled ovarian stimulation” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Cetrorelix side effects and safety

PepBank has 57 safety results from studies of cetrorelix. 55 of them come from studies in people.

Safety results from studies (57)

In IVF patients, serious ovarian overstimulation occurred less often with the cetrorelix protocol than with buserelin. (Archives of gynecology and obstetrics, 2000)
In infertile ART patients, cetrorelix and ganirelix had similar safety profiles. (Fertility and sterility, 2005)
In COS patients, ovarian hyperstimulation cases did not differ significantly between cetrorelix and agonist protocols. (European journal of obstetrics, gynecology, and reproductive biology, 2005)
In RA patients, adverse event rates were similar with cetrorelix and placebo. (Scandinavian journal of rheumatology, 2014)
In assisted fertilization patients, miscarriage rates were lower with the cetrorelix protocol than with the triptorelin protocol. (Fertility and sterility, 2013)
In normoresponder IVF/ICSI patients, ovarian hyperstimulation did not differ significantly between cetrorelix and leuprolide. (Advances in therapy, 2008)
In lower-weight Asian women, ovarian hyperstimulation syndrome did not differ significantly between cetrorelix 0.2 and 0.15 mg/day. (Taiwanese journal of obstetrics & gynecology, 2006)
In RA patients with high gonadotropins, adverse event rates were similar with cetrorelix and placebo. (PloS one, 2015)
In infertile IVF-ET patients, ovarian hyperstimulation syndrome occurred less often with cetrorelix than with the depot triptorelin protocol. (Fertility and sterility, 2000)
In infertile PCOS patients, ovarian hyperstimulation syndrome was less frequent with cetrorelix than with buserelin. (The journal of obstetrics and gynaecology research, 2010)
In IVF/ICSI patients receiving cetrorelix 0.25 mg, abortion rate was 7%. (Taiwanese journal of obstetrics & gynecology, 2008)
In IVF/ICSI patients receiving cetrorelix, abortion occurred in 12/60 patients. (Journal of obstetrics and gynaecology of India, 2017)
In normal men, the only side-effect seen after cetrorelix was redness at the injection site that disappeared within 30 min. (The Journal of clinical endocrinology and metabolism, 1992)
In women with uterine fibroids, no flare-up effect was observed during cetrorelix treatment. (Contraception, fertilite, sexualite, 1999)
One cetrorelix-treated patient had a grade 4 anaphylactoid reaction controlled with cortisol and cimetidine. (Gynecologic oncology, 2003)
In women with uterine fibroids and satisfactory hormone suppression, no initial flare-up occurred with cetrorelix. (Human reproduction, 1998)
In normal men given daily cetrorelix, the only other side-effect seen was mild redness at the injection site that faded within an hour. (Clinical endocrinology, 1994)
In normal women, very slight, transient injection-site redness occurred after cetrorelix. (Fertility and sterility, 1994)
In normal men, no serious side effects were observed after cetrorelix. (Acta endocrinologica, 1993)
In patients with BPH, all cetrorelix dosage regimens were well tolerated. (European urology, 2008)
Severe ovarian hyperstimulation occurred in less than 1% of cycles with the cetrorelix protocols. (Reproductive biomedicine online, 2003)
In patients with BPH, all cetrorelix dosages had good tolerability. (Urology, 2010)
After cetrorelix ovarian stimulation, ectopic pregnancy occurred in 3.4% of pregnancies. (Fertility and sterility, 2001)
In IVF patients, doctors withheld hCG for threatened ovarian overstimulation less often with cetrorelix than with buserelin. (Archives of gynecology and obstetrics, 2000)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.25 mg/day	Human	human	Not reported	Not reported	Randomized trial in people · n = 427	Jain 2016
0.25 mg/d	Human	human	Not reported	Not reported	Randomized trial in people · n = 146	Kolibianakis 2011
0.25 mg	Human	human	subcutaneous	From leading follicle reaching 14 mm until trigger day	Randomized trial in people · n = 100	Tandulwadkar 2023
5 mg/day on days 1 and 2; 3 mg/day on days 3-5	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 99	Kåss 2014
0.25 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 61	Lee 2008
5mg days1-2; 3mg days 3-5	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 53	Kåss 2015
5 mg on days 1, 8, 15 and 22	Human	human	Not reported	4 weeks	Randomized trial in people	Engel 2007
10 mg on days 1, 8, 15 and 22	Human	human	Not reported	4 weeks	Randomized trial in people	Engel 2007
10 mg on days 1 and 15	Human	human	Not reported	4 weeks	Randomized trial in people	Engel 2007
60 mg followed by 30 mg 2 weeks later	Human	human	Intramuscular	Not reported	Randomized trial in people	Debruyne 2010
0.25 mg daily increased to 0.5 mg	Human	human	Not reported	Not reported	Randomized trial in people	Lin 2008
3 mg single dose	Human	human	Not reported	Not reported	Randomized trial in people · n = 460	Vlaisavljevic 2003
3 mg, with daily 0.25 mg if hCG criteria were unmet after 4 days	Human	human	SC	Not reported	Randomized trial in people · n = 185	Wilcox 2005
0.125 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 123	Dawood 2017
0.25 mg daily	Human	human	subcutaneous	3 days	Randomized trial in people · n = 99	Cheng 2020
0.25 mg daily when follicles reached at least 14 mm	Human	human	Not reported	Not reported	Randomized trial in people · n = 93	Moraloglu 2008
0.125 mg daily	Human	human	injection	Not reported	Randomized trial in people · n = 87	Lai 2013
0.25 mg/day	Human	human	Not reported	Not reported	Randomized trial in people · n = 86	Chang 2013
0.125 mg/day	Human	human	injection	Not reported	Randomized trial in people · n = 76	Tiboni 2011
3 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 74	Sauer 2004
0.25 mg daily	Human	human	Not reported	Not reported	Randomized trial in people · n = 66	Cheung 2005
0.25 mg/d	Human	human	Not reported	Not reported	Randomized trial in people · n = 65	Zikopoulos 2005
0.2 mg/day	Human	human	Not reported	From menstrual day 8 until hCG administration	Randomized trial in people · n = 58	Chang 2006
0.25 mg daily during late follicular phase	Human	human	Not reported	Not reported	Randomized trial in people · n = 48	Akman 2001
0.25 mg daily when the leading follicle reached 14 mm	Human	human	Not reported	Not reported	Randomized trial in people · n = 42	Kahraman 2009
0.25 mg/day	Human	human	Not reported	From follicle diameter >=14 mm until HCG administration	Randomized trial in people · n = 41	Ragni 2001
0.25 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 40	Streda 2009
1-5 mg peptide base	Human	human	subcutaneous	single dose	Randomized trial in people · n = 36	Erb 2001
10 mg CET/glu	Human	human	subcutaneous	Once weekly for 4 weeks	Randomized trial in people · n = 36	Erb 2002
CET/glu 5 or 10 mg peptide base; CET/wat 10 mg peptide base	Human	human	subcutaneous	Once weekly for 4 weeks	Randomized trial in people · n = 36	Erb 2002
0.25, 0.5, 1.0, 2.0 and 5.0 mg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 30	Behre 1992
3mg cetrorelix acetate	Human	human	Not reported	Not reported	Randomized trial in people · n = 30	Rashidi 2011
1.0 mg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 10	Behre 1992
2.0 mg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 10	Behre 1992
5.0 mg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 10	Behre 1992
3 mg	Human	human	Not reported	single dose	Randomized trial in people	Olivennes 2000
5 mg weekly x4, 10 mg every 2 weeks x2, or 10 mg weekly x4	Human	human	subcutaneous	Not reported	Randomized trial in people	Debruyne 2008
Single 3 mg dose	Human	human	Not reported	Not reported	Randomized trial in people	Martínez 2010
0.25 mg/d	Human	human	Not reported	Not reported	Trial in people without random groups	Graziano 2013
0.25 mg/day	Human	human	Not reported	Not reported	Trial in people without random groups · n = 1,066	Olivennes 2003

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label reports prescription use. The regimen below is label information.

Reported routines and cautions

What people use it for

Inhibition of premature LH surges in women undergoing controlled ovarian stimulationS1

Reported regimens

Regimens that community sources report for Cetrorelix. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
US label regimen for women undergoing controlled ovarian stimulation. Cetrotide cetrorelix acetate powder for injection supplies 0.25 mg cetrorelix per vial.Official label dosing of an approved product	subcutaneous injection	0.25 mg per dose	once daily	Start on stimulation day 5 (morning or evening) or day 6 (morning). Continue daily until the day of hCG administration.	Single official US label source.	S1

Cautions

The label contraindicates hypersensitivity to cetrorelix acetate, extrinsic peptide hormones, mannitol, GnRH, or other GnRH analogs. It also contraindicates known or suspected pregnancy, lactation, and severe renal impairment. Fertility specialists prescribe treatment and exclude pregnancy first. Hypersensitivity reactions can occur with the first dose. Treatment is not advised in women with severe allergic conditions.S1

Status notes

EMA lists Cetrotide as authorised in the European Union. Its indication covers premature ovulation prevention during controlled ovarian stimulation before assisted reproduction.S2

Community sources

S1Cetrotide US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This check established one selected US label regimen. It did not establish a separate non-vendor community regimen. This record does not reproduce every administration instruction or safety detail. The full US label and EU product information apply within their respective jurisdictions.

Questions and more

Ask a question about cetrorelix

The answer links to every study it uses.

What does the evidence say about cetrorelix?Is cetrorelix tested in people?Compare with Triptorelin (Trelstar, Decapeptyl)Compare with Kisspeptin-10

Sources

Database: PepBank data for cetrorelix (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about cetrorelix

Cetrorelix

ApprovedNot banned in sport

Also known as Cetrotide

What it is

Synthetic analog, 10 amino acids

Approval

Approved in the US and EU (Cetrotide)

In sport

Not listed as banned by WADA

Studies

83 studies with results. 82 of them gave cetrorelix, with 486 results.
436 in people40 in animals10 in lab cells

Best study in people

Randomized controlled trial with 427 people (2016)

Clinical trials

95 registered: 8 active or planned, 14 with posted results

Community use

Inhibition of premature LH surges in women undergoing controlled ovarian stimulation

Dose as reported

Class

Species

Route

Duration

Design

Source

0.25 mg/day

Human

human

Not reported

Randomized trial in people · n = 427

Jain 2016

0.25 mg/d

Human

human

Not reported

Randomized trial in people · n = 146

Kolibianakis 2011

0.25 mg

Human

human

subcutaneous

From leading follicle reaching 14 mm until trigger day

Randomized trial in people · n = 100

Tandulwadkar 2023

5 mg/day on days 1 and 2; 3 mg/day on days 3-5

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 99

Kåss 2014

0.25 mg

Human

human

Not reported

Randomized trial in people · n = 61

Lee 2008

5mg days1-2; 3mg days 3-5

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 53

Kåss 2015

5 mg on days 1, 8, 15 and 22

Human

human

Not reported

4 weeks

Randomized trial in people

Engel 2007

10 mg on days 1, 8, 15 and 22

Human

human

Not reported

4 weeks

Randomized trial in people

Engel 2007

10 mg on days 1 and 15

Human

human

Not reported

4 weeks

Randomized trial in people

Engel 2007

60 mg followed by 30 mg 2 weeks later

Human

human

Intramuscular

Not reported

Randomized trial in people

Debruyne 2010

0.25 mg daily increased to 0.5 mg

Human

human

Not reported

Randomized trial in people

Lin 2008

3 mg single dose

Human

human

Not reported

Randomized trial in people · n = 460

Vlaisavljevic 2003

3 mg, with daily 0.25 mg if hCG criteria were unmet after 4 days

Human

human

Not reported

Randomized trial in people · n = 185

Wilcox 2005

0.125 mg

Human

human

Not reported

Randomized trial in people · n = 123

Dawood 2017

0.25 mg daily

Human

human

subcutaneous

3 days

Randomized trial in people · n = 99

Cheng 2020

0.25 mg daily when follicles reached at least 14 mm

Human

human

Not reported

Randomized trial in people · n = 93

Moraloglu 2008

0.125 mg daily

Human

human

injection

Not reported

Randomized trial in people · n = 87

Lai 2013

0.25 mg/day

Human

human

Not reported

Randomized trial in people · n = 86

Chang 2013

0.125 mg/day

Human

human

injection

Not reported

Randomized trial in people · n = 76

Tiboni 2011

3 mg

Human

human

Not reported

Randomized trial in people · n = 74

Sauer 2004

0.25 mg daily

Human

human

Not reported

Randomized trial in people · n = 66

Cheung 2005

0.25 mg/d

Human

human

Not reported

Randomized trial in people · n = 65

Zikopoulos 2005

0.2 mg/day

Human

human

Not reported

From menstrual day 8 until hCG administration

Randomized trial in people · n = 58

Chang 2006

0.25 mg daily during late follicular phase

Human

human

Not reported

Randomized trial in people · n = 48

Akman 2001

0.25 mg daily when the leading follicle reached 14 mm

Human

human

Not reported

Randomized trial in people · n = 42

Kahraman 2009

0.25 mg/day

Human

human

Not reported

From follicle diameter >=14 mm until HCG administration

Randomized trial in people · n = 41

Ragni 2001

0.25 mg

Human

human

Not reported

Randomized trial in people · n = 40

Streda 2009

1-5 mg peptide base

Human

human

subcutaneous

single dose

Randomized trial in people · n = 36

Erb 2001

10 mg CET/glu

Human

human

subcutaneous

Once weekly for 4 weeks

Randomized trial in people · n = 36

Erb 2002

CET/glu 5 or 10 mg peptide base; CET/wat 10 mg peptide base

Human

human

subcutaneous

Once weekly for 4 weeks

Randomized trial in people · n = 36

Erb 2002

0.25, 0.5, 1.0, 2.0 and 5.0 mg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 30

Behre 1992

3mg cetrorelix acetate

Human

human

Not reported

Randomized trial in people · n = 30

Rashidi 2011

1.0 mg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 10

Behre 1992

2.0 mg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 10

Behre 1992

5.0 mg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 10

Behre 1992

3 mg

Human

human

Not reported

single dose

Randomized trial in people

Olivennes 2000

5 mg weekly x4, 10 mg every 2 weeks x2, or 10 mg weekly x4

Human

human

subcutaneous

Not reported

Randomized trial in people

Debruyne 2008

Single 3 mg dose

Human

human

Not reported

Randomized trial in people

Martínez 2010

0.25 mg/d

Human

human

Not reported

Trial in people without random groups

Graziano 2013

0.25 mg/day

Human

human

Not reported

Trial in people without random groups · n = 1,066

Olivennes 2003

Context

Route

Amount

How often

How long

Agreement

Sources

US label regimen for women undergoing controlled ovarian stimulation. Cetrotide cetrorelix acetate powder for injection supplies 0.25 mg cetrorelix per vial.Official label dosing of an approved product

subcutaneous injection

0.25 mg per dose

once daily

Start on stimulation day 5 (morning or evening) or day 6 (morning). Continue daily until the day of hCG administration.

Single official US label source.

Cetrorelix

Cetrorelix at a glance

What is cetrorelix?

The history of cetrorelix

Cetrorelix structure and chemistry

What cetrorelix studies show

Sex hormones and fertility

Bones and joints

Cancer

Immune system and inflammation

Cholesterol and blood fats

Kidneys and bladder

Key cetrorelix studies

Cetrorelix clinical trials

Is cetrorelix approved?

Cetrorelix side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about cetrorelix

Related peptides

Sources

Cetrorelix

Cetrorelix at a glance

What is cetrorelix?

The history of cetrorelix

Cetrorelix structure and chemistry

What cetrorelix studies show

Sex hormones and fertility

Bones and joints

Cancer

Immune system and inflammation

Cholesterol and blood fats

Kidneys and bladder

Key cetrorelix studies

Cetrorelix clinical trials

Is cetrorelix approved?

Cetrorelix side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about cetrorelix

Related peptides

Sources